Who We Are

rngen is a virtual pharmaceutical company () at the forefront of developing next-generation therapeutics for diseases driven by inflammation and oxidative stress. As an advanced preclinical-stage company, we focus on designing first-in-class Systems Chemico-Pharmacology Drugs (SCPDs) that precisely modulate disease pathways. Our lead candidate, KYC, represents a breakthrough approach to treating acute and chronic conditions by targeting inflammatory and oxidative stress-related damage. Through a cutting-edge, virtual drug development model, rngen is accelerating scientific innovation, optimizing clinical translation, and ensuring that life-changing therapies reach patients worldwide.

Our Mission

At rngen, our mission is to positively change patient outcomes through transformative science, revolutionize treatment in complex, intractable disease conditions, and drive innovation in systems pharmacology therapy development.

What Sets Us Apart

  • Pioneering Systems Pharmacology for Unmet Medical Needs – The unique mechanism of action of our SCPD drugs confers optimizes specificity and minimizes off-target toxicity.
  • Robust Preclinical Data Validating Clinical Potential – Our comprehensive preclinical studies demonstrate compelling pharmacodynamics, systemic efficacy, and a well-defined safety profile in multiple disease models. The research has been peer-reviewed, NIH-funded, and validated in translational studies, establishing a clear roadmap toward first-in-human trials.
  • Scalability & Market Potential in High-Value Therapeutic Areas – With a target patient population in the millions, our lead program addresses a multi-billion-dollar market opportunity in inflammation and oxidative stress related diseases, where current treatment options are limited or ineffective. Beyond our lead asset, we have a scalable pipeline designed to expand into adjacent therapeutic indications, ensuring long-term revenue potential and strategic optionality for partners and investors.
  • Expert Leadership & Strategic Partnerships – Our management team and advisory boards brings decades expertise spanning drug discovery, clinical development, regulatory strategy, and commercialization. We have active collaborations with leading academic institutions, contract research organizations (CROs), and strategic industry partners, positioning us for a seamless transition into clinical development.

Our Pipeline & Focus Areas

We are currently developing a robust pipeline targeting inflammation and oxidative stress related disease conditions. Our lead candidate, KYC, is progressing towards, IND and CTA filing in Sickle Cell disease, Bronchopulmonary Dysplasia, and Respiratory Distress Syndrome. Additional programs focus on Multiple Sclerosis, Traumatic Brain Injury, Chronic Traumatic Encephalopathy, and Ischemic Stroke.

Why Partner with Us?

rngen offers investment opportunities in a high-impact sector with a clear path to return on investment and commercialization. Our innovative approach, strong IP portfolio, and commitment to collaborative partnerships position us for rapid growth and long-term success.